×

RNS Number : 7636P

Gresham House PLC

22 November 2016

 

22 November 2016

Gresham House plc ("Gresham House" or the "Company")

(AIM: GHE)

GRESHAM HOUSE REBRANDS FORESTRY DIVISION AND COMPLETION OF FIRST ACQUISITON BY GRESHAM HOUSE FORESTRY FUND

Gresham House plc, the specialist asset manager focused on alternative asset management strategies ("the Company") is pleased to announce the re-branding of its dedicated forestry asset management business, Aitchesse Ltd, as Gresham House Forestry ("GHF").  

GHF manages £238 million of assets on behalf of endowments, institutions, family offices and private investors and was acquired by the Company in November 2015.  The re-branding follows the successful £15 million first close of the Gresham House Forestry Fund LP ("The Fund"), which is targeting a total fundraising of £50 million at final close in 2017. 

In addition, the Company is pleased to confirm that the Fund has now completed its first investment through the purchase of five forests in the west of Scotland for £12 million referred to in the recent announcement on 31 October 2016.  The Fund is targeting annual returns of 10% including a yield of between 2% and 4%. 

Gresham House now has three divisions formed within its specialist asset management platform managing c.£375 million of third party assets:

‒     Strategic Public Equity managing a quoted investment company Gresham House Strategic plc ("GHS") and a Limited Partnership ("SPE Fund LP");

 

‒     Private Equity managing listed investment company LMS Capital plc; and

 

‒     Real Assets, formed through the establishment of its Forestry business managing third party assets through segregated mandates, managed accounts and the Gresham House Forestry Fund LP.

Tony Dalwood, Chief Executive of Gresham House plc said

"We are nearly two years into the development of Gresham House as a 'go-to' provider of alternative asset management strategies. We enter 2017 with a clear plan to continue to grow organically and with a number of corporate opportunities being appraised which would enable us to continue to scale our specialist asset management platform and accelerate the path to profitability, working closely alongside strategic partners and shareholders."

 

Enquiries:

Gresham House plc
Anthony Dalwood	+44 (0) 20 3837 6270
Montfort Communications, PR Adviser
Gay Collins	+44 (0) 203 770 7906
Rory King	greshamhouse@montfort.london
Liberum
Neil Elliot/Jill Li	+44 (0) 20 3100 2000

 

www.greshamhouse.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAKMMZMGMKGVZZ

Close

×

RNS Number : 7650P

Midatech Pharma PLC

22 November 2016

 

 

 

 

22 November 2016

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech provides update on agreement with Emergex Vaccines

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that following the licence granted to Emergex Vaccines Limited (announced 4 January 2016) Midatech has received an upfront technology access fee and option payment of £450,000 under the terms of the contract.  

 

This exclusive licensing agreement covers the use of Midatech's proprietary gold nanoparticle platform in the development of vaccines for influenza, meningitis, bacterial pneumonia, Ebola virus, Marburg virus and viruses within the Arbovirus class such Zika and Dengue. This is the first deployment of Midatech's gold nanoparticles as a conventional vaccine for infectious disease.

 

Under the agreement, the licence, together with the Service and Manufacturing Agreement for both the synthesis and development manufacturing of cGMP material for clinical trials, was novated from Emergex Vaccines Limited to a related entity Emergex Vaccines Holding Limited ("Emergex"), a private UK biotechnology company focused on developing synthetic T-cell vaccines against new and emerging infectious diseases.

 

Midatech will continue to be entitled to receive certain milestone and royalty payments, as well as service fees, as part of the arrangement.

 

Commenting on the announcement, Dr. Jim Phillips, CEO of Midatech Pharma, said: "I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease, which perfectly complements our type 1 diabetes collaboration in antigen specific immunotherapy, and our early-stage internal programs which address auto-immune disease and immuno-oncology."

 

David Jackson of Emergex added: "The expansion of the Midatech licence with Emergex is important for the development of cross-reactive or universal vaccines against infectious agents sharing common genetic characteristics such as flavi viruses within the Arbovirus group. There were 380 million new cases of Dengue last year and Zika is becoming a global health problem. The licence with Midatech now allows Emergex to develop vaccines that are not restricted to a single flavi virus but potentially act as a universal vaccine against Zika, Dengue and other flavi viruses. This is a continuation of our universal influenza vaccine program which also targets genetic components common to all influenza viruses. Our synthetic T cell mediated vaccines should also be able to safely immunize pregnant women and provide co-immunisation of the foetus which may be required for prevention of the congenital Zika syndrome."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

 

– Ends –

 

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Emergex Vaccines Holding Limited

Storme Moore-Thornicroft

Tel: +44 (0) 7766 705 871

 

Notes for Editors

 

About Midatech Pharma PLC

 

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a US commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and our proprietary gold nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.110 staff in four countries. For further company information see: www.midatechpharma.com

 

About our gold nanoparticle (GNP) technology

The patented gold nanoparticle (GNP) technology has been developed to improve key parameters when bound to existing and new drugs. GNPs comprise of a core of gold metal atoms to which an organic layer of carbohydrates or glycans (e.g. glucose, galactose or lactose) are attached via gold-sulphur bonds. Linkers for therapeutic agents (e.g. small molecules and chemotherapeutics) and peptides are attached to the gold core during the formation process. This process involves intricate and scalable synthesis that produces multi-component particles that may deliver multiple drug molecules to the targeted site. The GNP platform has potential uses in oncology, immunology/ auto-immunology and neurology, amongst other uses.

 

About Emergex Vaccines Holding Limited

 

Emergex was formed with the vision of tackling the global threats of infectious disease by utilising a novel T-cell synthetic vaccine technology. These vaccines are quick to develop, inexpensive to make, do not require cold chain and can be made quickly in quantity, thus overcoming many of the disadvantages of traditional vaccine technologies. Many developed nations have a national defence strategy of stockpiling large amounts of certain vaccines for use in the event of pandemics or terrorist activity.  The current practice is very expensive and the Emergex technology could greatly increase the quantities of vaccine available and substantially decrease the costs over time.

Emergex's lead products include a triple target vaccine against Zika, Dengue and Chikungunya, and vaccines against Ebola and a pandemic flu.

 

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialise products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCPGGBCGUPQPGG

Close

×

Neville Registrars is delighted to welcome Pressure Technologies plc as the newest addtion to its list of client companies.

Pressure Technologies listed on AIM in June 2007 with the goal of building a highly profitable group of companies, specialising in technology for the containment and control of liquids and gases in pressure systems.

Further information can be found on the Company's website: http://www.pressuretechnologies.com/home

Close

×

Neville Registrars is delighted to welcome Intelicrypt Tactical Solutions Limited as the newest addtion to its list of client companies.

 

Close

×

RNS Number : 5178P

The Mission Marketing Group PLC

18 November 2016

 

 

 

 

 

17 industry awards for Mission Agencies

 

 

The Mission Marketing Group plc ('the missiontm', "the Company", AIM: TMMG), the marketing communications and advertising group, is delighted to announce that two Agencies of the missiontm, bigdog and Chapter, collectively scooped a record 17 wins at The Drum Cream Awards held on 16 November.

 

bigdog secured the coveted Grand Prix award for its 'Party Animals' campaign on behalf of World Meat Free Day, marking the second consecutive year the Agency has received the accolade. In addition, bigdog and Chapter each won a further eight awards, making it the largest haul to date at Cream for both Agencies.

 

David Morgan, Chairman of the missiontm, commented: "These Awards are the latest in a long history of success for missiontm Agencies and again recognise that we have some of the very best talent in creative advertising and design across the Midlands, East, South West and Wales. I'm extremely proud of what we continue to achieve."

 

Enquiries   David Morgan, Chairman   Peter Fitzwilliam, Finance Director   The Mission Marketing Group plc	020 7462 1415
Geoff Nash/James Thompson (Corporate Finance) Stephen Norcross (Corporate Broking)
finnCap Limited	020 7220 0500

 

 

the missiontm is a network of entrepreneurial marketing communications Agencies employing over 950 people in the UK, Asia and San Francisco. The Group comprises a complementary mix of integrated generalists, specialists in specific marketing/communications activities and specialists in particular market sectors, all providing award-winning solutions to national and international Clients.  www.themission.co.uk

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAFFDFAWFMSELF

Close

×

RNS Number : 3941P

Genedrive PLC

17 November 2016

 

RNS  

 

For release: 17 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

genedrive plc Announces CE-IVD Certification for Genedrive® Human Genotyping Test

 

Approval of IL28B Test Further Validates Genedrive® Platform for Rapid Point of Care Human Genotyping

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, today announces the CE-IVD certification of its rapid Genedrive® IL28B SNP human genotyping test. The test is performed in 50 minutes from a buccal cheek swab using the Genedrive® hand-held real-time PCR instrument. The CE-IVD certification further validates Genedrive® as a technology platform for pharmacogenomics.

 

David Budd, CEO of genedrive plc, said: "We are now looking to partner with Pharma and Contract Research Organisations to support the development of SNP assays for clinical trials and clinical applications. Through our development of the IL28B test, we have defined a rapid pathway for the generation of a quick, accurate, and effective human genotyping tests that can be deployed at the point of need. While the treatment of HCV has evolved since we started the EU sponsored IL28B programme, the outcome clearly shows how our innovative technology can be put into practice in pharmacogenomics applications."

 

The Genedrive® platform and its polymorphism genotyping capabilities make it an appropriate solution for on the spot stratification, negating the need for costly and time consuming patient recall whilst central laboratory tests are processed.  Similarly, the low instrument cost, simplicity of operation, and connectivity options make it an ideal platform for deployment to large numbers of coordinated trial sites.

 

The data supporting the CE-IVD application showed that the Genedrive® human genotyping IL28B SNP test was 100% accurate in detecting inherited genetic polymorphisms in HCV patients when compared to the current 'gold-standard' laboratory test (Roche TaqMan® PCR). Genedrive® produces results in 50 minutes compared to the standard approach which uses a blood sample and which can have a service lab return time of 2 -3 weeks for results.

 

The company announced in August that that the Genedrive® IL28B human genotyping test will be used in the STOP-HCV-1 clinical trial being run by STOP-HCV, a consortium designed to use stratified medicine to optimise the treatment of patients with Hepatitis C Virus infection. The trial is designed to assess the effectiveness of different treatment durations with Direct Acting Antiviral treatments on HCV Genotype 1 patients (http://www.stop-hcv.ox.ac.uk/stop-hcv-1-trial).

 

–  Ends  –

 

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEAXFKFLXKFFF

Close

×

RNS Number : 4472P

BMR Group PLC

17 November 2016

 

BMR Group PLC ("BMR" or the "Company")

Kabwe Plant Construction Update

The Board is pleased to announce the following update on the progress at Kabwe.

Plant Construction Update

a) Civil Works

Marking out and excavation of the thickener, leach and precipitation tank foundations will be completed this week ready for steel fixing, shuttering and concreting to start. Two crews will be working in tandem to complete as much of this work as possible before the Christmas holiday.

b) Mechanical – Tanks, Thickeners and Filter Presses

All stainless steel tanks for the leach/precipitation/zinc re-leach have been ordered and will be completed by Christmas ready for shipment. The mild steel precipitation and lead leach tanks manufactured in Kabwe are currently undergoing inspection and testing prior to acceptance. The lime and limestone mixing tanks for the precipitation stage are currently under construction. Agitator mechanisms for the tanks have started to arrive on site. 

A supply and delivery contract to Kabwe has been negotiated with Roytec South Africa for all thickeners, filter presses and the automated flocculant dosing units. By our negotiation of the contract covering all these items, important savings have resulted to the Company.  Roytec South Africa is able to offer commissioning services and technical backup in Zambia.

c) Horizontal Belt Filter (HBF)

A redundant, unused HBF has been located and purchased from a copperbelt mining company in Zambia at a significant saving for the Company.  This purchase is viewed by the Board as a key piece of mineral processing equipment and arrangements are being made to move the unit to Kabwe in the coming weeks.

 d) Electrical

An additional 500 kVa capacity transformer has been installed and commissioned at the plant site as part of the programme to meet the anticipated demand.

Plant Commissioning and Production Ramp-up Target Dates

Provisional target date for plant commissioning has been delayed to mid 2017, as a result of the lead times on deliveries of major items of capital equipment, when BMR will initially process wash plant tailings ("WPT") feed.  BMR then envisages ramping-up production in two further stages.

After commissioning, the Board estimates that approximately 12 months will be required to assess fully the performance of the plant as designed before embarking on the first stage to increase production. This will be achieved through an incremental increase in tonnage throughput by the introduction of an equal tonnage of Star Zinc high grade ore to combine with the WPT feed.  The result will be a significant increase in zinc production.  Lead production will not be affected. With the exception of the acid brine leach and the lead recovery sections, this first stage plant expansion can be achieved by adding modules to the existing plant.

The second stage ramp up is planned to coincide with the processing of leach plant residue ("LPR") and imperial smelting furnace slag ("ISFS"). The tonnage throughput is likely to be made up of 2:1 ratio of LPR and ISFS combined with an equal tonnage of Star zinc ore. As announced on 3 October 2016, additional metallurgical investigation work is required to assess the extent of the modifications required to the acid brine leach section of the plant. This metallurgical test work will now be extended to investigate the impact of introducing the Star Zinc ore to the feed.  Details of the test work results will be advised in due course. Provisional target date for commissioning this second stage is 2020.

Vanadium

The appointment of Alfred H Knight, an accredited metallurgical lab in Kitwe has been accepted by the Minerals Consultancy Corporation (MCC) to carry out confirmatory metallurgical test work to meet the criteria for the JORC report. In the announcement of 3 October 2016, it was stated that the in-situ ISFS vanadium potential amounted to 9,000 tonnes, which is equivalent to a grade of 0.6%, which was the assayed figure of the random sample used for the test work.

Appointment of a Plant Construction Manager

The Board is pleased to announce that it has contracted the services of Jeff Livesey to manage the construction of the Company's tailings re-treatment plant at Kabwe. Jeff is a professional plant construction manager who has recently completed a series of projects for different divisions of the Anglo American group in South Africa.  He will be resident in Kabwe during construction until the plant is commissioned.

 

Note: This announcement has been reviewed by Geoff Casson, B.Sc. (Hons), PhD, R Eng (Zambia), Member Engineering Institute of Zambia (Metallurgy), General Manager of the Company's Zambian subsidiary, Enviro Processing Ltd, who is a Qualified Person in accordance with the guidance note for Mining, Oil & Gas Companies issued by the London Stock Exchange in respect of AIM Companies.

A further announcement concerning anticipated costings and process and output volumes will be made in due course.

Similarly, BMR expects to make a further announcement shortly concerning the exercise of the option agreement with Bushbuck Resources Limited of Zambia to acquire its Large Scale Prospecting Licence 19653-HQ-LPL (Star Zinc), as first announced on 16 August 2016.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

 

Alex Borrelli, Chairman, commented: " We are delighted to have secured Jeff's construction and management skills at this important stage of the construction of the plant.  Shareholders will note from this update the considerable progress that has already been achieved which is within our cost budget for the plant." 

Ends

For further information:

BMR Group PLC                                                                                 020 7734 7282

Alex Borrelli, CEO and Chairman

 

WH Ireland Limited                                                                           020 7220 1666

NOMAD and Joint Broker

Chris Fielding, Head of Corporate Finance

 

Peterhouse Corporate Finance                                                        020 7469 0930

Joint Broker  

Lucy Williams/ Duncan Vasey/ Heena Karani

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLIFSTLSLDLIR

Close

×

RNS Number : 1458P

Altitude Group PLC

15 November 2016

 

Altitude Group plc

("Altitude", the "Company" or "Group")
 

First "Click to Ship" (C2S) Web Sites Launched

Altitude, the provider of technology solutions for the personalised products industry is pleased to announce that the first "Click to Ship" web sites were launched and went live with distributors over the last two weeks in accordance with the timetable outlined in our Interim Results announced on 20 September 2016 for the six months ended 30 June.

As at 14 November 2016 the first 11,000 web sites had been launched for distributors. All the sites were issued through our first key trading partners in the USA, Aprinta and AI Mastermind.

Each C2S web site provides a full ecommerce platform to Personalised Product resellers, including a product catalogue, product visualisation and production-ready artwork functionality at no upfront cost. The Company is remunerated as a percentage of revenue processed through the web sites. The Board believes this compelling offer is potentially structurally changing in the highly fragmented personalised and promotional product, signage and printed wearables industries within the USA, a market estimated to be worth more than $22 billion per annum.

The C2S solution and basis of trading remains the key strategic priority of the Company. The scale and speed of roll out will continue to be carefully managed and evaluated. The Company looks forward to making further announcements of continued progress as we continue to roll out the solution and explore similar opportunities. 

 

Enquiries:

 

Altitude Group plc Peter Hallett, Chairman	07887 987469
WH Ireland Limited (Nominated Adviser and Broker) Tim Feather/Ed Allsopp	0113 394 6600

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLLFLDLELSLIR

Close

×

RNS Number : 1500P

Midatech Pharma PLC

15 November 2016

 

 

 

 

 

 

15 November 2016

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech selects MTR104 candidate for treatment of liver cancer

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, has today announced that, following intensive research over the past two years with its gold nanoparticle technology, it has selected its wholly-owned candidate compound, MTR104, to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018.

 

The programme is focused on advanced liver cancer where current chemotherapeutic treatment options are limited and the typical survival period is six months. Midatech is pursuing improved forms of cancer therapy based on combining marketed chemotherapeutic medicines with tumour-targeting molecules or peptides on the same nanoparticle-based conjugate.  The aim is to allow highly toxic drugs to be specifically targeted to and delivered at the tumour cells while sparing normal tissue, thereby reducing side effects and enhancing efficacy.

 

Commenting on this candidate selection, Jim Phillips, CEO of Midatech Pharma, remarked: "In-line with the internal development strategy as announced in conjunction with the Company's recent fundraise, candidate selection of MTR104 follows a comprehensive research and development programme that included very encouraging targeting and tumour reduction data in the preclinical setting, and we are looking forward to progressing MTR104 through development into the clinic as we hope to make a difference for patients suffering from this severe disease."

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary-Jane Elliott / Ivar Milligan / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a US commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and our proprietary gold nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.[110] staff in four countries. For further company information see: www.midatechpharma.com

 

About our gold nanoparticle (GNP) technology

The patented gold nanoparticle (GNP) technology has been developed to improve key parameters when bound to existing and new drugs. GNPs comprise of a core of gold metal atoms to which an organic layer of carbohydrates or glycans (e.g. glucose, galactose or lactose) are attached via gold-sulphur bonds. Linkers for therapeutic agents (e.g. small molecules and chemotherapeutics) and peptides (e.g. insulin) – are attached to the gold core during the self-formation process. This process involves intricate yet uncomplicated synthesis that produces multi-component particles that may deliver multiple drug molecules to the targeted site. The GNP platform has potential uses in Oncology, Immunology/ Auto-immunology and Neurology, amongst others.

 

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEAPFLFESKFFF

Close

×

RNS Number : 1833P

WANdisco Plc

15 November 2016

 

15 November 2016

 

WANdisco plc

("WANdisco" or the "Company")

 

Contract win

 

Leading online gaming provider Playtika selects WANdisco's Amazon cloud solution

 

WANdisco (LSE: WAND), a leading provider of enterprise-ready, non-stop cloud software solutions, is pleased to announce it has secured an important contract win for its Amazon S3 Cloud solution, available in Amazon's AWS Marketplace, with global online gaming company Playtika.

 

Playtika selected WANdisco Fusion after an extensive tender process in which it was found to be the only solution that could transfer the large volumes of continuously changing data generated by Playtika, to the cloud without impacting the gaming experience of Playtika's six million daily players across 190 countries.  Playtika's games consistently rank among the top grossing games on Apple's App Store, Google Play and Facebook.

 

With the deployment of WANdisco Fusion's patented technology, Playtika's Amazon S3 and on-premise environments operate in parallel to ensure seamless disaster recovery in the event of an unplanned outage.

 

The deal is based on Terabytes of data being replicated by WANdisco Fusion on a subscription basis.

 

The award of this contract is directly in-line with the Company's focus of deploying its market leading WANdisco Fusion cloud solution via a number of sales channel partnerships, including Amazon, Cisco, IBM, Google, Hewlett Packard, Microsoft and Oracle.

 

Previously, the Company announced a $1.5 million contract with a US financial services institution with over $200 billion in assets secured through WANdisco's partnership with Oracle and a $775,000 agreement with a major global bank headquartered in Europe for WANdisco's Subversion Multisite Plus ALM (Application Lifecycle Management) software.

 

David Richards, Chief Executive Officer and Interim Chairman of WANdisco, commented:

 

"This is an important contract win for WANdisco as it not only demonstrates our ability to reap real benefit through our channel partnerships, but Playtika's selection of WANdisco Fusion further demonstrates that the capabilities we offer companies considering cloud migration and hybrid cloud deployments are truly unique.

 

"Playtika found that no other solution could move active, continuously changing data to the cloud without downtime and disruption and keep both their on-premise and cloud environments in sync. This further validates our vision that the Company's ability to manage unprecedented volumes of active data in the cloud is firmly at the heart of our growth strategy."

 

For further information, please contact:

 

WANdisco plc	via Vigo Communications
David Richards, CEO and Interim Chairman
Vigo Communications	+44 (0)207 830 9700
Jeremy Garcia / Fiona Henson / Antonia Pollock www.vigocomms.com
Investec (Joint Broker and NOMAD)	+44 (0)207 597 4000
Christopher Baird / Dominic Emery
UBS (Joint Broker) Rahul Luthra / Sandip Dhillon	+44 (0)207 567 8000

 

 

About WANdisco

WANdisco (LSE: WAND) is the world leader in Active Transactional Data Replication™. Its patented technology provides continuous consistent access to changing data anytime and anywhere with no downtime and no disruption. WANdisco's patented technology serves crucial high availability (HA) requirements, including migration to cloud, Hadoop Big Data and Application Lifecycle Management (ALM), Subversion, Git and Gerrit.  

 

WANdisco works directly with Fortune 1000 companies around the world and in all sectors to ensure their data, whether it is on-premise or in the cloud, gives them the real insight they need. WANdisco has an OEM with IBM and is also partnered with Amazon Web Services, Cisco, Google Cloud Platform, Hewlett Packard Enterprise, Microsoft Azure and Oracle to resell its patented technology. WANdisco is committed to the ODPi Interoperable Compliance Program to ensure its products are interoperable across a wider range of commercial Apache™ Hadoop® Platforms.

 

For additional information, please visit www.wandisco.com.

 

About Playtika

Playtika, led by its Co-Founder and CEO, Robert Antokol, pioneered free-to-play games on social networks and mobile platforms.  It is the creator of such popular titles as Slotomania, House of Fun and Bingo Blitz, which consistently rank among the top-grossing games on Apple's App Store, Google Play and Facebook.  Playtika's games are played daily by more than 6 million people in 190 countries, in 12 languages and on more than 10 platforms.  Playtika was founded in 2010 and is headquartered in Herzliya, Israel with offices in Argentina, Australia, Belarus, Canada, Japan, Romania, Ukraine and the United States.

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALIFSRLELELIR

Close